Earn-Out Shares (non-vested) Earn Out Shares Nonvested [Member] Earnout or earn-out refers to a pricing structure in mergers and acquisitions where the sellers must "earn" part of the purchase price based on the performance of the business. RSL 2021 EIP Roivant Sciences Ltd 2021 Equity Incentive Plan [Member] The Roivant Sciences Ltd Equity Incentive Plan 2021 also known as (the "RSL 2021 EIP"). Investments in Equity Securities Investment, Policy [Policy Text Block] Income/(loss) from disregarded entities Effective Income Tax Rate Reconciliation, Income (Loss) From Disregarded Entities, Amount Effective Income Tax Rate Reconciliation, Income (Loss) From Disregarded Entities, Amount Award Timing Predetermined Award Timing Predetermined [Flag] Number of vesting tranches meeting share price hurdles Number of Vesting Tranches Meeting Share Price Hurdles Number of Vesting Tranches Meeting Share Price Hurdles Common shares aggregate offering price authorized Common Shares Offering Price Authorized The common shares aggregate offering price authorized to issue under equity offering program. Tax deficiencies (excess tax benefits) from stock-based compensation Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent Entity File Number Entity File Number Additional Paid-in Capital Additional Paid-in Capital [Member] Tabular List, Table Tabular List [Table Text Block] Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Research tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Other comprehensive (loss) income: Other Comprehensive Income (Loss), Tax [Abstract] Adjustment to Compensation: Adjustment to Compensation [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Loss from discontinued operations before income taxes attributable to noncontrolling interests Less: Net loss from discontinued operations, net of tax attributable to noncontrolling interests Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest Accounts payable Increase (Decrease) in Accounts Payable, Trade Entity Addresses [Table] Entity Addresses [Table] Share-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Wholly-owned Subsidiaries Address - Switzerland Wholly-owned Subsidiaries Address - Switzerland [Member] Wholly-owned Subsidiaries Address - Switzerland Schedule of Stock by Class [Table] Stock, Class of Stock [Table] Cost of revenues Operating Costs The total amount of operating cost and expense. Issuance of the Company's common shares under employee stock purchase plan (in shares) Issuance of the company's common shares under employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Lease liabilities Deferred Tax Assets, Lease Liabilities Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the lease liabilities. Schedule of Cash, Cash Equivalents, and Restricted Cash Schedule of Cash and Cash Equivalents [Table Text Block] Total current tax expense Current Income Tax Expense (Benefit) Adjustment to Compensation, Amount Adjustment to Compensation Amount Principles of Consolidation Consolidation, Policy [Policy Text Block] Share-based compensation Share-Based Payment Arrangement, Noncash Expense Foreign-derived intangible income Effective Income Tax Rate Reconciliation, FDII, Amount Annual net operating loss utilization limitation percentage Annual Net Operating Loss Utilization Limitation Percentage Percentage of future taxable income for tax years and other net operating losses can be carried forward indefinitely as well, with an annual limitation on utilization. Stock Options Share-Based Payment Arrangement, Option [Member] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Percent Effective Income Tax Rate Reconciliation, Percent [Abstract] Schedule of Unrealized Losses (Gains) on Significant Equity Method Investments Schedule of Unrealized Loss (Gain) on Equity Method Investments [Table Text Block] For all equity method investments in an unrealized loss (gain) position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of equity method investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value). Antidilutive Securities [Axis] Antidilutive Securities [Axis] Asset impairment charges Asset Impairment Charges Shareholders’ equity attributable to Roivant Sciences Ltd. Equity, Attributable to Parent Research and development Disposal Group Including Discontinued Operation Research and Development Expense Amount of research And development expense attributable to disposal group, including, but not limited to, discontinued operation. Insider Trading Policies and Procedures [Line Items] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Stock issued during period (in shares) Stock Issued During Period, Shares, New Issues Liability instruments measured at fair value Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value Concentrations Concentration Risk, Credit Risk, Policy [Policy Text Block] Nondeductible executive compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation, Amount Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation, Amount Liabilities and Shareholders’ Equity Liabilities and Equity [Abstract] Cover [Abstract] Cover [Abstract] Money market funds Cash and Cash Equivalents, Fair Value Disclosure Discontinued Operations Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Maximum Maximum [Member] Options exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Net loss attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Debt securities, available-for-sale, unrealized loss position Debt Securities, Available-for-Sale, Unrealized Loss Position Potential material future milestone payments Maximum Potential Future Milestone Payments The maximum potential future milestone payment pursuant to certain key asset acquisition and license agreements. Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Issuance of the Company’s common shares, net of issuance costs (in shares) Stock Issued During Period, Shares, Net Issuance Costs Number of stock issued during the period net of issuance costs. Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Asset acquisition, research and development expense in process Asset Acquisition, Research and Development Expense in Process Amount of asset acquisition research and development expense in-process. (Loss) income from continuing operations before income taxes Total (loss) income from continuing operations before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Entity Shell Company Entity Shell Company Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Schedule of Activity for PSUs Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block] Gain on sale of Telavant net assets Gain on sale of Telavant net assets Gain (loss) on sale of assets Gain on sale of Telavant net assets Gain (Loss) on Sale of Assets Amount of gain (loss) on sale of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. Schedule of Cash Payments by Jurisdiction, Net of Refunds Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Term of trailing trading days, weighted average price use to calculate performance condition of PSUs Period of Trailing Trading Days, Weighted Average Trading Price used to Calculate Performance Condition of PSUs Period of trailing trading days, weighted average trading price used to calculate performance Condition of PSUs in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Comprehensive loss attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Award Timing MNPI Considered Award Timing MNPI Considered [Flag] (Loss) income from continuing operations, net of tax (Loss) income from continuing operations, net of tax Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Genevant Sciences GmbH Genevant Sciences GmbH [Member] Genevant Sciences GmbH Operating lease liabilities Operating Lease, Liability, Current Milestone receivable from sale of discontinued operations Milestone Receivable from Sale of Discontinued Operations Amount of Milestone Receivable for the disposal of assets and liabilities, including discontinued operation. Document Fiscal Period Focus Document Fiscal Period Focus Aggregate grant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Granted Intrinsic value of grants award under share-based payment arrangement. Excludes share and unit options. Nondeductible/(nontaxable) changes in the fair value of investments and loss from equity method investments Effective Income Tax Rate Reconciliation, Changes In Fair Value Of Investments And Loss From Equity Method Investment, Percent Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax-effect of changes in the fair value of investments and loss from equity method investment. Award Timing Method Award Timing Method [Text Block] (Loss) income from continuing operations, net of tax (in dollars per share) Income (Loss) from Continuing Operations, Per Basic Share Furniture and fixtures Furniture and Fixtures [Member] Fair value of vested earnout liability Fair Value Of Vested Earnout Liability Fair Value Of Vested Earnout Liability Award Type [Axis] Award Type [Axis] Parent Company Parent Company [Member] Investment, Name [Domain] Investment, Name [Domain] Share-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Disposition of Telavant Noncontrolling Interest, Increase Decrease from Disposition The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the disposition of subsidiary. Trading Symbol Trading Symbol 2030 Lessee, Operating Lease, Liability, to be Paid, Year Four Other Noncash, Other Amount of expense or loss included in net income that result in no cash flow, classified as other. Hurdle price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Hurdle Price Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Hurdle Price Valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent % of PSUs Share Based Compensation Arrangement by Share Based Payment Award, Percentage of PSUs Allocated The percentage of PSUs allocated to each tranche during performance period. Entity Address, City or Town Entity Address, City or Town Earn-Out Shares, Public Warrants and Private Placement Warrants [Table] Earn-Out Shares, Public Warrants and Private Placement Warrants [Table] Schedule for earn-out shares, public warrants and private placement warrants. Royalty-related receipts percentage Royalty-Related Receipts Percentage Royalty-Related Receipts Percentage President and Chief Operating Officer President and Chief Operating Officer [Member] Person with designation of president and chief operating officer. Marketable Securities [Line Items] Marketable Securities [Line Items] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Restricted Stock Units Restricted common stock (non-vested) Restricted Stock Units (RSUs) [Member] Statement of Income Location, Balance [Domain] Statement of Income Location, Balance [Domain] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Entity Emerging Growth Company Entity Emerging Growth Company Schedule of Unrealized Positions for Marketable Securities Debt Securities, Held-to-Maturity [Table Text Block] Options outstanding, beginning balance (in shares) Options outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Performance stock units performance condition satisfied (in shares) PSUs Performance Condition Satisfied, Shares PSUs Performance Condition Satisfied, Shares Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Less: tenant improvement allowance Lessee Operating Lease Liability Tenant Improvement Allowance Amount of tenant improvement allowance adjustment for operating lease. Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Cap (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Cap Price Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Cap Price Chief Executive Officer Chief Executive Officer [Member] U.S. Treasury securities, held-to-maturity, Gross Unrealized Losses Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss Period to exercise warrants after business combination Period to Exercise Warrants After Business Combination Period after the completion of a business combination when warrants will become exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Current taxes: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Valuation allowance increase (decrease) Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Number of shares issued (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Number of RSUs Number of CVARs Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Restatement Determination Date Restatement Determination Date Right-of-use assets Deferred Tax Liabilities, Right-of-use Assets Amount of deferred tax liability attributable to taxable temporary differences from right of use assets. Income tax expense Total income tax expense Income Tax Expense (Benefit) Income (loss) from discontinued operations, net of tax (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Balance at beginning of period Balance at end of period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Less: present value adjustment Operating Lease Liability Present Value Adjustments Amount of present value adjustment for operating lease. Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Issuance of the Company’s common shares in connection with equity incentive plans, net of forfeitures, and tax withholding payments (in shares) Stock Issued During Period, Shares, In Connection With Equity Incentive Plans and Tax Withholding Payments The number of shares issued in connection with equity incentive plans and tax withholding payments. Long-Term Purchase Commitment [Table] Long-Term Purchase Commitment [Table] Cash and cash equivalents and marketable securities Total cash, cash equivalents, and marketable securities Cash, Cash Equivalents, and Short-Term Investments (Loss) income from continuing operations, net of tax, attributable to Roivant Sciences Ltd., diluted Income (Loss) from Continuing Operations, Net of Tax, Attributable To Parent, Dulited Income (Loss) from Continuing Operations, Net of Tax, Attributable To Parent, Dulited Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations and Disposal Groups [Abstract] Other current assets Increase (Decrease) in Other Current Assets Non-cash lease expense Operating Lease, Right-of-Use Asset, Periodic Reduction Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Proceeds from exercise of the Company’s and subsidiary stock options Proceeds from Stock Options Exercised United States Federal and Other Income Tax Paid, Federal, after Refund Received All Trading Arrangements All Trading Arrangements [Member] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Recent Transactions and Developments Recent Transactions and Developments [Text Block] The entire disclosure for recent transactions and development. Accrued expenses Total accrued expenses Accrued Liabilities, Current Intangible assets Deferred Tax Assets, Goodwill and Intangible Assets Nontaxable income Effective Income Tax Rate Reconciliation, Tax Exempt Income, Percent Contingencies Commitments and Contingencies, Policy [Policy Text Block] Other Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Deferred tax liabilities Deferred Tax Liabilities, Gross [Abstract] Number of service-vested shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Service Vested , Outstanding, Number Number of fully service vested options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. Non-vested, beginning balance (in shares) Non-vested, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Gain on litigation settlement Gain on litigation settlement Litigation Settlement, Gain Cash payment received for sale of assets Cash Payment Received For Sale Of Assets Amount of cash payment received for sale of assets. Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation November 2021 CVAR Grants November 2021 CVARs (non-vested) November 2021 Capped Value Appreciation Rights Grants [Member] Grant date of Capped Value Appreciation Rights (CVARs). Effective Income Tax Rate Reconciliation [Table] Effective Income Tax Rate Reconciliation [Table] Debt securities, available-for-sale U.S. Treasury securities, available-for-sale, Fair Value Debt Securities, Available-for-Sale, Excluding Accrued Interest Equity Method Investments and Joint Ventures [Abstract] Equity Method Investments and Joint Ventures [Abstract] Estimated useful lives Property, Plant and Equipment, Useful Life Subsequent Event Subsequent Event [Member] Schedule of Fair Value Assumptions Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Description of Business and Liquidity [Line Items] Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] PEO Total Compensation Amount PEO Total Compensation Amount Money market funds Money Market Funds [Member] Permanent disallowed IPR&D Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount Issuance of the Company’s common shares, net of issuance costs Stock Issued During Period, Value, Net Issuance Costs Stock issued during the period value, net of issuance costs. Melissa Epperly [Member] Melissa Epperly Research and Development, Contract to Perform for Others [Table] Research and Development, Contract to Perform for Others [Table] Pfizer Pfizer [Member] Name of the entity. Equity Components [Axis] Equity Components [Axis] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Receivable from sale of discontinued operations Receivable from Sale of Discontinued Operations Amount of receivable for the sale or disposal of assets and liabilities, including discontinued operation. Product revenue, net Product [Member] Number of reportable segments Number of Reportable Segments MAAC Sponsor Patient Square Capital Limited Liability Company [Member] Name of the sponsor company. Cash received Proceeds from Sale of Discontinued Operation The Cash inflow resulting from the sale of discontinued operation. Entity Address, Country Entity Address, Country Entity Address, State or Province Entity Address, State or Province Payments on principal portion of finance lease obligations Finance Lease, Principal Payments Impairment loss on operating lease right-of-use assets Operating Lease, Impairment Loss Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Security, Excluded EPS Calculation [Table] Total current liabilities Current liabilities Liabilities, Current Fifth Tranche Share-Based Compensation Award, Tranche Fifth [Member] Fifth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period. Milestone received from sale of discontinued operations Milestone Received From Sale Of Discontinued Operations Amount of Milestone Received for the disposal of assets and liabilities, including discontinued operation. Consideration receivable under liquidation preference Disposal Group Including Discontinued Operation Liquidation Consideration Receivable Amount of consideration receivable under the liquidation preference of preference shares pursuant to merger agreement. Individual: Individual [Axis] Proceeds from sale of subsidiary interests Proceeds from Divestiture of Interest in Consolidated Subsidiaries Income Tax Jurisdiction [Domain] Income Tax Jurisdiction [Domain] Intrinsic value of options exercised Intrinsic Value of Options Exercised The intrinsic value of options exercised during the period. Document Annual Report Document Annual Report Research and development share-based compensation Research and Development Expense [Member] Schedule of Fair Value Assumptions Schedule Of Share Based Payment Award PS Us Valuation Assumptions [Table Text Block] Tabular disclosure of the significant assumptions used during the year to estimate the fair value of PSUs Valuation Assumptions. Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Other Income Tax Paid, State And Local And Foreign, After Refund Received Income Tax Paid, State And Local And Foreign, After Refund Received Capitalized research and development Deferred Tax Asset, In-Process Research and Development Entity Interactive Data Current Entity Interactive Data Current Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] President and Chief Investment Officer President and Chief Investment Officer [Member] Person with designation of president and chief investment officer. 129 Available-for-Sale Marketable Securities Available-for-Sale Marketable Securities In Unrealized Loss Position [Member] Available-for-Sale Marketable Securities In Unrealized Loss Position Share repurchase program, increased authorized, amount Share Repurchase Program, Increased Authorized, Amount Share Repurchase Program, Increased Authorized, Amount Change in fair value of liability instruments Gain (loss) on fair value of liability instruments Change in fair value of liability instruments Gain (Loss) on Fair Value of Liability Instruments Amount of gain (loss) on fair value of liability instruments. Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Options exercisable, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Net operating loss Deferred Tax Assets, Operating Loss Carryforwards Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Cash exercise price (in dollars per share) Cash Exercise Price The exercise price per common share on a cash basis to exercise warrants. Ownership [Domain] Ownership [Domain] Depreciation Deferred Tax Liabilities, Depreciation Amount of deferred tax liability attributable to taxable temporary differences from depreciation. Other assets Other Assets, Noncurrent Entity Central Index Key Entity Central Index Key Anti-FcRn franchise—other clinical and nonclinical Anti Fc Rn Franchise Other Clinical And Nonclinical [Member] Service provided for maintenance, diagnosis and treatment of physical and mental health, classified as other clinical and nonclinical PEO Name PEO Name Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Trading day period for earn-out shares Number of Trading Days Allowed to Calculate Earn-Out Share Price Threshold Number of trading days allowed to calculate earnout share price during vesting period, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Recent Transactions and Developments [Abstract] Recent Transactions and Developments [Abstract] Recent Transactions and Developments [Abstract] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Balance at beginning of period Balance at end of period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] First Tranche Share-Based Payment Arrangement, Tranche One [Member] Total operating lease cost Operating Lease, Costs Amount of lease cost recognized by lessee for operating lease contract. Exercise price of warrants (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Income/(loss) from disregarded entities Effective Income Tax Rate Reconciliation, Income (Loss) From Disregarded Entities, Percent Effective Income Tax Rate Reconciliation, Income (Loss) From Disregarded Entities, Percent RSI Lease Agreement Roivant Sciences Inc Lease Agreement [Member] Subsidiaries lease agreement for office space. Exercise Price Award Exercise Price Entity Filer Category Entity Filer Category Class of Stock [Domain] Class of Stock [Domain] Amounts attributable to Roivant Sciences Ltd.: Income Amounts Attributable to Parent, Disclosures [Abstract] Share-based payment arrangement, nonvested award, excluding option, cost not yet recognized, amount Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Income tax benefit at Bermuda statutory tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Subsequent Event Type [Axis] Subsequent Event Type [Axis] Accretion of discount and amortization of premium on held-to-maturity marketable securities, net Accretion (Amortization) of Discounts and Premiums, Held-to-Maturity Marketable Securities Accretion (Amortization) of Discounts and Premiums, Held-to-Maturity Marketable Securities Number of marketable securities Number Of Debt Securities, Available-for-Sale Number Of Debt Securities, Available-for-Sale Marketable securities, available-for-sale Marketable Securities, Available-for-Sale [Abstract] Marketable Securities, Available-for-Sale Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Vesting [Domain] Vesting [Domain] Reversal of certain deferred tax assets Effective Income Tax Rate Reconciliation, Reversal of Certain Deferred Tax Assets, Percent Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to reversal of certain deferred tax assets. Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Research and development (includes $47,867, $39,780 and $32,400 of share-based compensation expense for the years ended March 31, 2026, 2025 and 2024, respectively) Research and development expense Research and Development Expense Accumulated Other Comprehensive (Loss) Income AOCI Attributable to Parent [Member] Loss from operations Disposal Group, Including Discontinued Operation, Operating Income (Loss) Ownership [Axis] Ownership [Axis] Change in fair value of debt Change in Fair Value of Debt, Discontinued Operations Amount of noncash change in the fair value of debt related to discontinued operations Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Fair Value as of Grant Date Award Grant Date Fair Value Pulmovant Pulmovant [Member] a wholly-owned subsidiary of the Company, in-licensed certain intellectual property rights in exchange for a $14.0 million upfront cash payment. Proceeds from exercise of the Company’s warrants Proceeds from Warrant Exercises Net operating losses Operating Loss Carryforwards Expected stock price volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Other stock based awards and instruments issued Other Stock Based Awards and Instruments Issued [Member] The other stock based awards and instruments issued related to the awards consisting of stock units. Granted (in shares) Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Title and Position [Domain] Title and Position [Domain] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Unrecognized compensation expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Proceeds from issuance of subsidiary common shares, net of issuance costs paid Proceed From Issuance Of Subsidiary Common Stock, Net Of Issuance Costs Proceed From Issuance Of Subsidiary Common Stock, Net Of Issuance Costs Schedule of Fair Value Calculation Using Significant Unobservable Inputs Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Share-based compensation Share-Based Compensation, Discontinued Operations Amount of noncash expense for share-based payment arrangement attributable to discontinued operations. Counterparty Name [Domain] Counterparty Name [Domain] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Two Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Options outstanding, weighted average remaining contractual life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Brepocitinib Brepocitinib [Member] Brepocitinib it represent selective inhibitor of non-receptor tyrosine-protein kinase TYK2 (tyrosine kinase 2) and tyrosine-protein kinase JAK1 (Janus kinase 1; JAK1) with potential immunomodulatory and anti-inflammatory activities. Title Trading Arrangement, Individual Title Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Intercompany reorganization Effective Income Tax Rate Reconciliation, Intercompany Reorganization, Percent Effective Income Tax Rate Reconciliation, Intercompany Reorganization, Percent Non-PEO NEO Non-PEO NEO [Member] Options outstanding, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Issuance of the Company’s common shares under employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Sale of Stock [Axis] Sale of Stock [Axis] U.S. Treasury securities, available-for-sale, Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Award Type [Domain] Award Type [Domain] 2027 Lessee, Operating Lease, Liability, to be Paid, Year One Maximum amount of contribution of base salary Maximum Amount of Annual Contribution Maximum amount of annual contribution an eligible employee can made under the employee stock purchase plan. Noncontrolling interests Equity, Attributable to Noncontrolling Interest Equity Awards Adjustments Equity Awards Adjustments [Member] Other Other Noncash Income (Expense) Gain on deconsolidation of subsidiaries Gain on deconsolidation of subsidiaries Gain on deconsolidation Deconsolidation, Gain (Loss), Amount Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Vesting of Earn-Out Shares Stock Issued During Period, Value, Vesting Of Earn-Out Shares Stock Issued During Period, Value, Vesting Of Earn-Out Shares Discontinued Operations, Disposed of by Sale Discontinued Operations, Disposed of by Sale [Member] Compensation Amount Outstanding Recovery Compensation Amount Deferred taxes: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Sale of interests in subsidiary Noncontrolling Interest, Sale of Interests in Subsidiary Amount of noncontrolling interest from sale of interests in subsidiary. Switzerland SWITZERLAND Less: Earnings allocated to subsidiary potentially dilutive common stock equivalents Earnings Allocated To Subsidiary Potentially Dilutive Common Stock Equivalents Earnings Allocated To Subsidiary Potentially Dilutive Common Stock Equivalents Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Issuance of subsidiary common shares to the Company and cash contributions to majority-owned subsidiaries Issuance of Subsidiary Common Shares to the Company and Capital Contributions to Subsidiaries The amount net common shares issued of subsidiary to the company and cash contributions to majority-owned subsidiaries. Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Accretion of discount and amortization of premium on available-for-sale marketable securities, net Accretion (Amortization) of Discounts and Premiums, Available-for-Sale Marketable Securities Accretion (Amortization) of Discounts and Premiums, Available-for-Sale Marketable Securities Anti-FcRn franchise—rheumatology diseases Anti Fc Rn Franchise Rheumatology Diseases [Member] Rheumatology diseases is a chronic progressive autoimmune disease that causes inflammation in the joints and surrounding tissues. MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Foreign rate differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Deductible federal taxes Effective Income Tax Rate Reconciliation, Deductible Federal Taxes, Amount Effective Income Tax Rate Reconciliation, Deductible Federal Taxes, Amount Employee Stock Employee Stock [Member] Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Long-Term Purchase Commitment [Line Items] Long-Term Purchase Commitment [Line Items] Financial Instruments [Domain] Financial Instruments [Domain] Cash decrease upon deconsolidation of subsidiaries Cash Divested from Deconsolidation Award Date [Domain] Award Date [Domain] Reclassification of earn-out shares liability to additional paid-in capital upon vesting Reclassification Of Earn-Out Shares Liability To Additional Paid-In Capital Upon Vesting Reclassification Of Earn-Out Shares Liability To Additional Paid-In Capital Upon Vesting Bermuda BERMUDA Performance Restricted Stock Units (at max) Performance Shares [Member] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Change in fair value of debt due to change in subsidiary credit risk Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss) Anti-FcRn franchise—dermatology diseases Anti Fc Rn Franchise Dermatology Diseases [Member] Dermatology diseases is a rare, chronic skin disease characterized by skin-specific disease activity, inflammation and eventually damage. Minimum Minimum [Member] Company Selected Measure Name Company Selected Measure Name Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Accounts payable Accounts Payable, Current Cash paid for operating lease liabilities Operating Lease, Payments Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Net (loss) income attributable to Roivant Sciences Ltd., diluted Net Income (Loss) Available to Common Stockholders, Diluted Class of warrant or right redemption (in dollars per share) Class of Warrant or Right Redemption Price Redemption price per share or per unit of warrants or rights outstanding. Description of Business and Liquidity [Abstract] Description of Business and Liquidity [Abstract] Description of Business and Liquidity [Abstract] Reclassification to additional paid-in capital upon vesting of Earn-Out Shares Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Reclassification Amount Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Reclassification Amount Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Second Tranche Share-Based Payment Arrangement, Tranche Two [Member] Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Segment Reporting Segment Reporting, Policy [Policy Text Block] Grant date fair value of options vested Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Research and development personnel-related expenses Personnel Related Expenses [Member] Represents Research and development personnel related expenses. Entity Small Business Entity Small Business Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Document Transition Report Document Transition Report Due after one year but within five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Underlying Securities Award Underlying Securities Amount Equity Component [Domain] Equity Component [Domain] Document Period End Date Document Period End Date Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Income Taxes Income Tax Disclosure [Text Block] United Kingdom UNITED KINGDOM Research and Development Arrangement, Contract to Perform for Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Short-term lease cost Short-Term Lease, Cost Options exercisable, weighted average remaining contractual life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Operating lease liabilities Increase (Decrease) in Operating Lease Liability Total shareholders’ equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Document Type Document Type Level 3 Fair Value, Inputs, Level 3 [Member] Net (Loss) Income per Common Share Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Marketable Securities [Table] Marketable Securities [Table] Additional paid-in capital Additional Paid in Capital Product and Service [Axis] Product and Service [Axis] Issuance of subsidiary common shares, net of issuance costs Stock Issued During Period, Value, Subsidiary Common Shares, Net Of Issuance Costs Stock Issued During Period, Value, Subsidiary Common Shares, Net Of Issuance Costs Investment in Datavant Class A units Datavant Holdings, Inc [Member] The name of related party. Variable lease cost Variable Lease, Cost Foreign currency transaction gains Foreign Currency Transaction Gain, before Tax Revenue Revenue Revenue from Contract with Customer, Excluding Assessed Tax Total current assets Current assets Assets, Current Statistical Measurement [Axis] Statistical Measurement [Axis] Forfeited/Canceled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Share repurchase program, authorized, amount Share Repurchase Program, Authorized, Amount Fair Value Measurements [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Disposal Group Name [Axis] Disposal Group Name [Axis] Proceeds from sales Proceeds From Sale Of Marketable Securities, Available-for-Sale Proceeds From Sale Of Marketable Securities, Available-for-Sale Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Cantonal and communal taxes Effective Income Tax Rate Reconciliation, Cantonal And Communal Taxes, Amount Effective Income Tax Rate Reconciliation, Cantonal And Communal Taxes, Amount Net (loss) income attributable to Roivant Sciences Ltd., basic Net Income (Loss) Available to Common Stockholders, Basic Marketable securities (held at fair value as of March 31, 2026) Marketable Securities, Current Share Repurchase Program [Domain] Share Repurchase Program [Domain] Income (loss) from discontinued operations before income taxes Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax Current liabilities: Liabilities, Current [Abstract] Research tax credits Deferred Tax Assets, Tax Credit Carryforwards, Research Total operating expenses Operating Expenses Level 1 Fair Value, Inputs, Level 1 [Member] Accrued expenses Increase (Decrease) in Accrued Liabilities Net (loss) income (in dollars per share) Earnings Per Share, Diluted License, milestone and other revenue License, Milestone and Other Revenue [Member] Represents the license, milestone, and other revenue. Non-cash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Immunovant, Inc. Immunovant, Inc. [Member] Name of subsidiary. Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Percentage of earn-out shares Percentage of Earn-Out Shares The collective percentage of earn-out shares. Sale of stock, number of shares issued in transaction (in shares) Sale of Stock, Number of Shares Issued in Transaction Sumitomo Pharma Co. Ltd. Sumitomo Pharma Co. Ltd. [Member] The name of related party. Intercompany reorganization Effective Income Tax Rate Reconciliation, Intercompany Reorganization, Amount Effective Income Tax Rate Reconciliation, Intercompany Reorganization, Amount Option purchase additional shares of common stock (in shares) Option to Purchase Additional Shares of Common Stock Number of additional shares of common stock option to purchase. Cantonal and communal taxes Effective Income Tax Rate Reconciliation, Cantonal And Communal Taxes, Percent Effective Income Tax Rate Reconciliation, Cantonal And Communal Taxes, Percent Description of Business and Liquidity Business Description and Basis of Presentation [Text Block] Derivative Liability, Statement of Financial Position [Extensible Enumeration] Derivative Liability, Statement of Financial Position [Extensible Enumeration] Income (loss) from discontinued operations, net of tax Income (loss) from discontinued operations, net of tax (Income) loss from discontinued operations, net of tax Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Auditor Location Auditor Location Equity Method Investments Equity Method Investments and Joint Ventures Disclosure [Text Block] Number of common shares issued to surrendering holder per warrant (in shares) Stock Issued During Period Number of Shares Issued to Surrendering Holder Per Warrant Number of common shares issued to surrendering holder per warrant during the period. Gross profit Gross Profit Repurchase of the Company’s common shares Stock Repurchased and Retired During Period, Value Common shares aggregate offering price authorized, remaining capacity available Common Shares Aggregate Offering Price Authorized, Remaining Capacity Available The common shares aggregate offering price authorized remaining capacity to issue under equity offering program. U.S. Treasury securities, held-to-maturity, Amortized Cost Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Current Redeemable units Redeemable Units, Amount Redeemable Units, Amount Money market funds Money Market Funds, at Carrying Value Change in fair value of debt and liability instruments Gain (Loss) on Fair Value of Debt and Liability Instruments Amount of gain (loss) on fair value of debt and liability instruments. Total Income Taxes Paid, Net Corporate bonds Corporate Bond Securities [Member] Investor Investor [Member] Nondeductible/(nontaxable) changes in the fair value of investments and loss from equity method investments Effective Income Tax Rate Reconciliation, Changes In Fair Value Of Investments And Loss From Equity Method Investment, Amount Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax-effect of changes in the fair value of investments and loss from equity method investment. Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Batoclimab Batoclimab [Member] Batoclimab Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Compensation-related expenses Employee-related Liabilities, Current Total lease payments Lessee, Operating Lease, Liability, to be Paid Unrealized losses on available-for-sale securities OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Subsidiaries Subsidiaries [Member] Warrant exercised (in shares) Public Warrant Cash Exercised Number of Public warrants cash exercised during the period. Dividend declared by subsidiary Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Issuance of the Company’s common shares in connection with equity incentive plans, net of forfeitures, and tax withholding payments Stock Issued During Period Value In Connection With Equity Incentive Plans And Tax Withholding Payments The value of stock issued in connection with equity incentive plans and tax withholding payments. Expiration Date Trading Arrangement Expiration Date Other liabilities Increase (Decrease) in Other Operating Liabilities Schedule of Significant Equity Method Investments Equity Method Investments [Table Text Block] Property and equipment, net Property, Plant and Equipment, Net Percentage of liquidation preference receivable Disposal Group Including Discontinued Operations Percentage of Liquidation Preference Receivable Percentage of liquidation preference receivable on preference shares pursuant to merger agreement. Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Entity Current Reporting Status Entity Current Reporting Status Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Consolidated Entities [Domain] Consolidated Entities [Domain] Public Warrants Public Warrants [Member] In finance, a warrant is a security that entitles the holder to buy or sell stock, typically the stock of the issuing company, at a fixed price called the exercise price. Statutory tax rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Earn-out shares, lock-up period Earn-Out Shares, Lock-Up Period Earn-Out Shares, Lock-Up Period Financial Instrument [Axis] Financial Instrument [Axis] Issuance of subsidiary common shares, net of issuance costs Stock Issued During Period, Value, Subsidiary Common Shares, Net Stock Issued During Period, Value, Subsidiary Common Shares, Net Deferred tax assets Deferred Tax Assets, Gross [Abstract] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Executive Category: Executive Category [Axis] LNP Technology (Genevant) LNP Technology [Member] LNP Technology Sale milestone receivable from sale of discontinued operations Sale Milestone Receivable from Sale of Discontinued Operations Amount of Sale milestone receivable for the disposal of assets and liabilities, including discontinued operation. Current Fiscal Year End Date Current Fiscal Year End Date Expected term, in years Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Loss) income before income taxes: Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest [Abstract] Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Common shares available for future grants (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Total liabilities at fair value Derivative Liability Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Immunovant Immunovant [Member] Immunovant Less: Loss from continuing operations, net of tax, attributable to noncontrolling interests Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest Upfront cash payment Upfront Cash Payment Received for Sale of Assets Amount of upfront cash payment received for sale of assets. Total operating expenses Disposal Group, Including Discontinued Operation, Operating Expense Revenue, net Disposal Group, Including Discontinued Operation, Revenue from Contract with Customer Excluding Assessed Tax Amount of revenue from contract with customer excluding assessed tax attributable to disposal group, including, but not limited to, discontinued operation. Schedule of Assets and Liabilities are Measured at Fair Value on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Cash and Cash Equivalents [Abstract] Potentially dilutive securities (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Weighted average shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Leases Lessee, Operating Leases [Text Block] Net cash provided by (used in) financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Measure: Measure [Axis] Contribution from minority interest holder to subsidiary Contribution from minority interest holder to subsidiary Proceeds From Contributions From Minority Interest Holder To Subsidiary Proceeds From Contributions From Minority Interest Holder To Subsidiary Expected allocation of fixed payment receivable Litigation Settlement, Expected Fixed Payment Receivable Litigation Settlement, Expected Fixed Payment Receivable Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Share repurchase program, remaining authorized, amount Share Repurchase Program, Remaining Authorized, Amount Disposal Group Classification [Domain] Disposal Group Classification [Domain] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Expected risk free interest rate Expected risk free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Entity Tax Identification Number Entity Tax Identification Number Research and development expenses Accrued Research and Development Expenses, Current Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to research and development expenses, due within one year or the normal operating cycle, if longer. Priovant Share Exchange Priovant Share Exchange [Member] Priovant Share Exchange Options outstanding, beginning balance (in dollars per share) Options outstanding, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Common stock, shares issued (in shares) Common Stock, Shares, Issued Weighted average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Earn-out share price (in dollars per share) Earn-Out Share Price The share price of earn-out share. Income Taxes [Line Items] Income Taxes [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Entity Public Float Entity Public Float Trading Arrangement: Trading Arrangement [Axis] Income tax payable Increase (Decrease) in Income Taxes Payable Total Shareholder Return Amount Total Shareholder Return Amount Changes in fair value of liability instruments, included in net loss Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Tranche Share Based Compensation Arrangements by Share Based Payment Award, Performance Condition During Period [Abstract] Share Based Compensation Arrangements by Share Based Payment Award, Performance Condition During Period [Abstract] Security Exchange Name Security Exchange Name Noncurrent liabilities Liabilities, Noncurrent CVARs Capped Value Appreciation Rights [Member] Capped value appreciation rights to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period. Stock repurchased during period (in shares) Stock Repurchased During Period, Shares Operating expenses: Less: Operating Expenses [Abstract] Other current liabilities Other Liabilities, Current Asset Class [Domain] Asset Class [Domain] Changes in fair value of investment in Datavant, included in net loss Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings Issuance of the Company's common shares related to settlement of transaction consideration (in shares) Stock Issued During Period, Shares, Common Shares Related to Settlement of Transaction Consideration The number of common shares issued related to settlement of transaction consideration. Statement [Line Items] Statement [Line Items] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents Cash and cash equivalents Total cash and cash equivalents Cash and Cash Equivalent Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Other development and discovery programs Other Development and Discovery Programs [Member] Research and development expenses classified as other development and discovery programs. Common Stock Common Shares Common Stock [Member] Vested (in shares) Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Net change in cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Private Placement Warrants Private Placement Warrants [Member] Security that gives the holder the right to purchase one share of common stock at a specific exercise price. Unrealized (Gain) Loss on Investment (in millions) Unrealized Gain (Loss) on Investments Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Underwritten Offering Underwritten Offering [Member] Underwritten Offering Statistical Measurement [Domain] Statistical Measurement [Domain] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five U.S. Treasury securities, available-for-sale, Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss Restricted cash (included in “Other current assets”) Restricted Cash, Current Related Party Transaction [Axis] Related Party Transaction [Axis] Asset Class [Axis] Asset Class [Axis] Meghan FitzGerald [Member] Meghan FitzGerald Income tax payable, noncurrent Taxes Payable, Noncurrent Taxes Payable, Noncurrent Leases [Abstract] Leases [Abstract] Net (loss) income per common share, basic: Earnings Per Share, Basic [Abstract] Schedule of Estimated Useful Life Property and Equipment, Estimated Useful Life [Table Text Block] Tabular disclosure of useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Net sales Disposal Group Including Discontinued Operation, Net Sales Amount of net sales attributable to disposal group, including, but not limited to, discontinued operation. Schedule of Discontinued Operations Disposal Groups, Including Discontinued Operations [Table Text Block] Earn-Out Shares, Public Warrants and Private Placement Warrants [Abstract] Earn-Out Shares, Public Warrants and Private Placement Warrants [Abstract] Earn-Out Shares, Public Warrants and Private Placement Warrants [Abstract] Taxable intercompany income/(deductible intercompany expense) Effective Income Tax Rate Reconciliation, Taxable Intercompany Income (Expense), Amount Effective Income Tax Rate Reconciliation, Taxable Intercompany Income (Expense), Amount U.S. Treasury securities, available-for-sale, Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Class of warrant or right, outstanding (in shares) Class of Warrant or Right, Outstanding Net (loss) income (in dollars per share) Earnings Per Share, Basic Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Liabilities: Liabilities, Fair Value Disclosure [Abstract] Common stock, capital shares reserved for future issuance, outstanding share, percentage Common Stock, Capital Shares Reserved For Future Issuance, Outstanding Share, Percentage Common Stock, Capital Shares Reserved For Future Issuance, Outstanding Share, Percentage Common shares reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Entity Addresses, Address Type [Axis] Entity Addresses, Address Type [Axis] Award Date [Axis] Award Date [Axis] Subtotal Deferred Tax Assets, Gross Discount rate Measurement Input, Discount Rate [Member] Total other comprehensive (loss) income Other Comprehensive Income (Loss), Net of Tax Schedule of Significant Segment Expenses Schedule of Segment Reporting Information, by Segment [Table Text Block] Income (loss) from discontinued operations, net of tax (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Schedule of Cash, Cash Equivalents, and Marketable Securities Cash, Cash Equivalent, and Investment [Table Text Block] U.S. Treasury securities, held-to-maturity, Gross Unrealized Gains Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain Measurement Input Type [Domain] Measurement Input Type [Domain] Accumulated accrual contractual costs Accumulated Contractual Costs Accumulated Contractual Costs RSL RSL [Member] RSL [Member] HanAll Biopharma Co., Ltd. (Immunovant) HanAll Biopharma Co., Ltd. (Immunovant) [Member] Name of the entity. Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Research and Development Expenses Research and Development Expense, Policy [Policy Text Block] Deductible federal taxes Effective Income Tax Rate Reconciliation, Deductible Federal Taxes, Percentage Effective Income Tax Rate Reconciliation, Deductible Federal Taxes, Percentage Litigation settlement, fixed payment Litigation Settlement, Amount Awarded from Other Party U.S. Treasury securities, available-for-sale US Treasury Securities, Available-for-Sale [Member] US Treasury Securities, Available-for-Sale Share-based compensation expense Share-Based Payment Arrangement, Expense Datavant Datavant [Member] Datavant Current assets: Assets, Current [Abstract] Total liabilities and shareholders’ equity Liabilities and Equity Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Number of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Taxes payable related to net settlement of equity awards Taxes Payable Related To Net Settlement Of Equity Awards Taxes Payable Related To Net Settlement Of Equity Awards Amounts reclassified from accumulated other comprehensive (loss) income Amounts reclassified from accumulated other comprehensive (loss) income Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Other assets Deferred Tax Assets, Other General and administrative share-based compensation General and Administrative Expense [Member] Equity Method Investment [Table] Equity Method Investment [Table] Accounting Policies [Abstract] Accounting Policies [Abstract] Schedule of Maturities of Operating Lease Liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] (Loss) income from continuing operations, net of tax Net income (loss) from continuing operations (Loss) income from continuing operations, net of tax Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period, fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Total consideration Consideration Received for Sale of Assets Amount of consideration received for sale of assets. Pay vs Performance Disclosure [Line Items] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Operating lease liability Total lease liabilities Operating Lease, Liability Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Cashless exercise price (in dollars per share) Exercise Price The exercise price per Common Share on a cashless basis to exercise warrants. Other liabilities Other Liabilities, Noncurrent Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Underwritten Offering - Shares Purchased By RSL Underwritten Offering - Shares Purchased By RSL [Member] Underwritten Offering - Shares Purchased By RSL Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Company Selected Measure Amount Company Selected Measure Amount 2029 Lessee, Operating Lease, Liability, to be Paid, Year Three Cash Cash Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Comprehensive (loss) income attributable to Roivant Sciences Ltd. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Litigation settlement receivable Litigation Settlements Receivable, Current Litigation Settlements Receivable, Current Measurement Input Type [Axis] Measurement Input Type [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] Name Measure Name Upfront cash payment Upfront Cash Payment The cash outflow associated with the upfront cash payment during the period. Schedule of (Loss) Income Before Income Taxes and Related Expense (Benefit) Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Due within one year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Schedule of Changes in Fair Value of the Level 3 Liabilities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Proceeds from maturities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale Class of Stock [Line Items] Class of Stock [Line Items] Schedule of Fair Value of Vested Stock Option Schedule of Share Based Payment Arrangement Fair Value of Vested Stock Option and Performance Option [Table Text Block] Tabular disclosure share based payment arrangement fair value of vested stock option and performance option. Income (loss) from discontinued operations, net of tax Income (loss) from discontinued operations before income taxes attributable to Roivant Sciences Ltd. Income (loss) from discontinued operations before income taxes attributable to Roivant Sciences Ltd. Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Taxes paid related to net settlement of equity awards Payments of Taxes for the Repurchase of Equity Payments of Taxes for the Repurchase of Equity. Legal Entity [Axis] Legal Entity [Axis] Total assets Assets Cowen Cowen and Company, LLC [Member] An affiliate with whom the entity entered into a sales agreement. Vested (in dollars per share) Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Liabilities transferred Disposal Group, Liabilities Amount classified as liabilities attributable to disposal group held for sale. Cash, Cash Equivalents and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Geographical [Domain] Geographical [Domain] Net liabilities sold Disposal Group, Net Assets (Liabilities) Amount classified as net assets (liabilities) attributable to disposal group held for sale. Income Taxes Income Tax, Policy [Policy Text Block] Cash flows from operating activities: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Research tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent President and Vant Chair President And Vant Chair [Member] President And Vant Chair Deconsolidation of subsidiaries Noncontrolling Interest, Decrease from Deconsolidation Assets: Assets, Fair Value Disclosure [Abstract] Number of tranches available for vesting Number of Vesting Tranches The number of tranches available for vesting of under 2024 Senior Executive Compensation Program. Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Operating lease right-of-use assets obtained in exchange for operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Cash, Cash Equivalents, and Short-Term Investments [Abstract] Cash, Cash Equivalents, and Short-Term Investments [Abstract] Aggregate value of shares exchanged on a cashless basis (in shares) Stock Issued During Period Shares Cashless Warrant Exercises Aggregate number of shares exchanged on a cashless basis during the period. Level 2 Fair Value, Inputs, Level 2 [Member] Document Financial Statement Error Correction [Flag] Document Financial Statement Error Correction [Flag] Percentage of maximum contribution of base salary Percentage of Maximum Contribution of Base Salary Percentage of maximum contribution of base salary an eligible employee can made under the employee stock purchase plan. Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Roivant Participation of Immunovant Stock offering Roivant participation of Immunovant Stock offering [Member] Roivant participation of Immunovant Stock offering [Member] Business Combination [Domain] Business Combination [Domain] Years Ending March 31, Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Schedule of Income Tax Expense Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Compensation-related expenses Compensation Related Expense Compensation related to one time cash retention bonus award to employees. Plan Name [Axis] Plan Name [Axis] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] PEO PEO [Member] ESPP initial offering period Employee Stock Purchase Program, Initial Offering Period Employee Stock Purchase Program, Initial Offering Period Schedule of Marketable Securities as Level 2 Measurements Within the Fair Value Hierarchy Investments Classified by Contractual Maturity Date [Table Text Block] Interest income Interest income Investment Income, Interest Change in fair value of debt due to change in subsidiary credit risk Change In Fair Value Of Debt Due To Change In Subsidiary Credit Risk Change In Fair Value Of Debt Due To Change In Subsidiary Credit Risk United States UNITED STATES Changes in assets and liabilities, net of effects from acquisition and divestiture: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Litigation settlement receivable Increase (Decrease) In Litigation Settlement Receivables Increase (Decrease) In Litigation Settlement Receivables Expected stock price volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate (Accumulated Deficit) / Retained Earnings Retained Earnings [Member] Number of trading days Number of Trading Days Number of trading days for common stock price to exceed threshold, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Income Tax Jurisdiction [Axis] Income Tax Jurisdiction [Axis] Repayment of debt by subsidiary Repayment of Long Term Debt and Convertible Debt by Subsidiary The cash outflow for debt repayment of long-term debt and convertible debt by subsidiary during the period. Schedule of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Share-Based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Summarized Consolidated Financial Information [Abstract] Income Statement [Abstract] Sale of Stock [Domain] Sale of Stock [Domain] Income tax payable Taxes Payable, Current Investments measured at fair value Aggregate Fair Value (in millions) Investment Investments, Fair Value Disclosure Reversal of certain deferred tax assets Effective Income Tax Rate Reconciliation, Reversal of Certain Deferred Tax Assets, Amount Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to reversal of certain deferred tax assets. Accrued interest Increase (Decrease) in Interest Payable, Net Product and Service [Domain] Product and Service [Domain] (Loss) income from continuing operations, net of tax (in dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share Net (loss) income Net (loss) income Net (loss) income Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Reportable Segment Reportable Segment [Member] Reportable Segment Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Liabilities at fair value Liabilities, Fair Value Disclosure Selling, general and administrative Disposal Group Including Discontinued Operation Selling, General and Administrative Expense Amount of selling, general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation. Organization, Consolidation and Presentation of Financial Statements [Abstract] Nontaxable income Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount Consideration to be received from milestone Future Milestone to be Received from Sale of Assets The future milestone to be received from sale of assets. Gain (loss) on sale of business, accumulated other comprehensive income (loss) Disposal Group, Including Discontinued Operation, Accumulated Other Comprehensive Income (Loss) Amount of accumulated other comprehensive income (loss) attributable to disposal group, including, but not limited to, discontinued operation. City Area Code City Area Code Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Cashless exercise of the Company’s warrants Cashless Exercise of the Company Common Stock Warrants Amount of cashless exercise of the company's common stock warrants in noncash investing or financing activities. Cash flows from investing activities: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] General and administrative (includes $298,297, $239,505, and $154,873 of share-based compensation expense for the years ended March 31, 2026, 2025 and 2024, respectively) General and administrative expenses General and Administrative Expense Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Accrued interest receivable Interest Receivable Gain on sale of subsidiary interests Gain (loss) on sale of interest in subsidiary Gain on sale of subsidiary interests Gain (Loss) on Sale of Interest in Subsidiary Amount of gain (loss) on sale of interest in subsidiaries. Effective Income Tax Rate Reconciliation [Line Items] Effective Income Tax Rate Reconciliation [Line Items] Schedule of Components of Operating Lease Expense Lease, Cost [Table Text Block] Change in fair value of investments Change in fair value of investments Gain (Loss) on Investments PSUs holding period before common shares may be sold by executive PSUs Holding Period Before Common Shares May be Sold by Executive The PSUs holding period before such common shares may be sold by the executive (subject to certain exceptions) in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Auditor Name Auditor Name Tax deficiencies (excess tax benefits) from stock-based compensation Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount Period of trailing trading days, weighted average trading price used to calculate performance condition Period of Trailing Trading Days, Weighted Average Trading Price used to Calculate Performance Condition Period of Trailing Trading Days, Weighted Average Trading Price used to Calculate Performance Condition Total estimated fair value of available-for-sale securities Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract] Warrants expiration period Warrants and Rights Outstanding, Term Supplemental disclosure of cash paid: Supplemental Cash Flow Information [Abstract] Other Performance Measure, Amount Other Performance Measure, Amount Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Ownership of subsidiary Ownership Of Shares, Percentage The percentage ownership of a subsidiary. Taxable intercompany income/(deductible intercompany expense) Effective Income Tax Rate Reconciliation, Taxable Intercompany Income (Expense), Percent Effective Income Tax Rate Reconciliation, Taxable Intercompany Income (Expense), Percent Marketable Securities Marketable Securities, Policy [Policy Text Block] Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Related and Nonrelated Parties [Domain] Related and Nonrelated Parties [Domain] Amount Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract] Milestone payment payable Milestone Payment Payable Amount of milestone payment payable. Vesting [Axis] Vesting [Axis] Cashless warrant exercised (in shares) Cashless Public Warrant Exercised Number of cashless public warrants exercised during the period. Other current assets Other Assets, Current Entity [Domain] Entity [Domain] Net cash (used in) provided by investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activity Settlement value percentage Litigation Settlement, Fixed Payment, Percentage Litigation Settlement, Fixed Payment, Percentage Document Fiscal Year Focus Document Fiscal Year Focus Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Total income tax expense Effective income tax rate reconciliation, percent Effective Income Tax Rate Reconciliation, Percent Operating lease cost Operating Lease, Cost Equity Method Investment, Nonconsolidated Investee [Axis] Equity Method Investment, Nonconsolidated Investee [Axis] Plan Name [Domain] Plan Name [Domain] Remaining weighted-average service period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Litigation settlement,contingent payment Litigation Settlement, Contingent Payment Receivable Litigation Settlement, Contingent Payment Receivable Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Valuation allowance Valuation allowance Deferred Tax Assets, Valuation Allowance Equity [Abstract] Equity [Abstract] Earn-Out Shares Earnout Shares [Member] The fair value of earn-out shares issued. Subsidiary Equity Incentive Plans Subsidiary Equity Incentive Plans [Member] Subsidiary equity incentive plans is a plan adopted by wholly owned and majority-owned or controlled subsidiaries of Roivant Sciences Ltd. Certain Balance Sheet Components [Abstract] Certain Balance Sheet Components [Abstract] Certain Balance Sheet Components [Abstract] Segment Information Segment Reporting Disclosure [Text Block] Cash awards Cash Retention Awards The amount of cash retention awards granted to executives. Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] U.S. Treasury securities US Treasury Securities [Member] Performance Stock Units Performance Stock Units [Member] Performance stock units. Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Roche Transaction Roche Transaction [Member] Name of business transaction. Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Restricted stock units and performance restricted stock units (non-vested) Restricted Stock and Performance Stock Units [Member] Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met and Share-based payment arrangement awarded for meeting performance target. Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Cost of revenues Disposal Group, Including Discontinued Operation, Costs of Goods Sold Schedule of One-time Cash Retention Awards Schedule Of Cash Retention Awards [Table Text Block] Tabular disclosure of cash retention awards. Leases Lessee, Leases [Policy Text Block] Volatility Measurement Input, Price Volatility [Member] Stock repurchased during period, value Stock Repurchased During Period, Value Depreciation and amortization Depreciation, Depletion and Amortization Sale of stock, consideration received on transaction Sale of Stock, Consideration Received on Transaction Foreign rate differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Arrangement Duration Trading Arrangement Duration Computers Computer Equipment [Member] Segments [Axis] Segments [Axis] Schedule of Activity for Capped Value Appreciation Rights Schedule of Capped Value Appreciation Rights Stock Units Activity [Table Text Block] Tabular disclosure of the capped value appreciation rights stock units activity. Other research and development expenses Other Research and Development Expenses [Member] Represents other research and development related expenses. Local Phone Number Local Phone Number Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Share price (in dollars per share) Stock price on date of grant (in dollars per share) Share Price Other Payment for (Proceeds from) Other Investing Activity Share-Based Compensation and Other Compensation Plans Share-Based Payment Arrangement [Text Block] Repurchase of the Company’s common shares (in shares) Stock Repurchased and Retired During Period, Shares Assets Assets [Abstract] Aggregate value of shares exchanged (in shares) Stock Issued During Period Shares Cash Warrant Exercises Aggregate number of shares exchanged during the period. Underlying Security Market Price Change Underlying Security Market Price Change, Percent Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Fair Value Measurements Fair Value Disclosures [Text Block] Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Shareholders’ equity: Equity, Attributable to Parent [Abstract] Cash Bonus Program Cash Bonus Program [Member] The company approved a special one-time cash retention bonus award to its employees. Investment, Name [Axis] Investment, Name [Axis] Operating lease liabilities, noncurrent Operating Lease, Liability, Noncurrent Entity Voluntary Filers Entity Voluntary Filers Unexercised public warrants (in shares) Class of Warrant or Right Unexercised Price of Warrants Number of shares unexercised of warrant redeemed during the period. Entity Registrant Name Entity Registrant Name Change in fair value of debt Disposal Group, Including Discontinued Operation, Change in Fair Value of Debt Amount of change in fair value of debt attributable to disposal group, including, but not limited to, discontinued operation. Other assets Increase (Decrease) in Other Noncurrent Assets Lessee, operating lease, discount rate Lessee, Operating Lease, Discount Rate Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Public and Private Warrants Public Warrants and Private Placement Warrants [Member] Security that gives the holder the right to purchase one share of Class A common stock at a specific exercise price. General and administrative personnel-related expenses Personnel Related Expenses, General and Administrative [Member] Represents General and Administrative Personnel Related Expenses. ESPP additional offering period Employee Stock Purchase Program, Additional Offering Period Employee Stock Purchase Program, Additional Offering Period Total assets at fair value Assets, Fair Value Disclosure Number of operating segments Number of Operating Segments Related and Nonrelated Parties [Axis] Related and Nonrelated Parties [Axis] Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Restatement Determination Date: Restatement Determination Date [Axis] Payment for redemptions of the Company’s warrants Payment for Warrant Redemptions The cash outflow associated with the warrant redemptions during period of the time. Nondeductible changes in the fair value of the Earn-Out Shares Effective Income Tax Rate Reconciliation, Nondeductible Changes In Fair Value Of Shares, Percent Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to significant shareholding exemption. Entity Addresses [Line Items] Entity Addresses [Line Items] Name Trading Arrangement, Individual Name Investment in equity securities, measurement input Fair Value Asset, Measurement Input Fair value asset, measurement input. Depreciation and amortization Depreciation and Amortization, Discontinued Operations Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] March 2020 CVAR Grants March 2020 CVARs March 2020 Capped Value Appreciation Rights Grants [Member] Grant date of Capped Value Appreciation Rights (CVARs). Share Repurchase Program [Axis] Share Repurchase Program [Axis] Nondeductible changes in the fair value of the Earn-Out Shares Effective Income Tax Rate Reconciliation, Nondeductible Changes In Fair Value Of Shares, Amount Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to substantial shareholding exemption. Income tax expense Discontinued Operation, Tax Effect of Discontinued Operation Name Awards Close in Time to MNPI Disclosures, Individual Name Earn-out share, measurement input Fair Value Earnout Shares Measurement Input The fair value measurement input for Earn-out shares. Non-vested, beginning balance (in dollars per share) Non-vested, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Restricted cash (included in “Other assets”) Restricted Cash, Noncurrent Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Other permanent adjustments Effective Income Tax Rate Reconciliation, Other Permanent Adjustments, Percent Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other permanent adjustments ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Asset Acquisition [Line Items] Asset Acquisition [Line Items] Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition U.S. Treasury securities, held-to-maturity US Treasury Securities, Held-to-Maturity [Member] US Treasury Securities, Held-to-Maturity Country Region Country Region Auditor Firm ID Auditor Firm ID Segments [Domain] Segments [Domain] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Axis] Noncurrent assets Assets, Noncurrent Operating lease right-of-use assets obtained and exchanged for operating lease liabilities Operating Lease Right-of-use Assets Obtained and Exchanged for Operating Lease Liabilities Amount of operating lease right-of-use assets obtained and exchanged for operating lease liabilities. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Laboratory and other equipment Laboratory And Other Equipment [Member] Laboratory And Other Equipment U.S. Treasury securities, held-to-maturity, Fair Value Debt Securities, Held-to-Maturity, Fair Value, Current Arbutus Investment in Arbutus common shares Arbutus Biopharma Corporation [Member] The name of related party. Other permanent adjustments Effective Income Tax Rate Reconciliation, Other Permanent Adjustments, Amount Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other permanent adjustments. Purchases Payments to Acquire Debt Securities, Available-for-Sale Common shares purchased by RSL (in shares) Stock Purchased During Period by Entity, Shares Number of new stock purchased during the period. Proceeds from issuance of the Company’s common shares under employee stock purchase plan Proceeds from Stock Plans All Executive Categories All Executive Categories [Member] Schedule of Components of Deferred Tax Assets (Liabilities) Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Common shares, par value $0.0000000341740141 per share, 7,000,000,000 shares authorized and 720,352,386 and 695,938,323 shares issued and outstanding at March 31, 2026 and 2025, respectively Common Stock, Value, Issued Exercise and vesting of subsidiary share awards Exercise And Vesting Of Subsidiary Share Based Awards Exercise And Vesting Of Subsidiary Share Based Awards Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Title and Position [Axis] Title and Position [Axis] Number of shares outstanding (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding Shares The number of share-based compensation arrangement by share-based payment award equity-based payment instruments, other than options, outstanding shares. Commitments and contingencies (Note 12) Commitments and Contingencies Pretax loss Income (Loss) from Disposal Group, before Income Tax Amount of before tax of income (loss) from a disposal group. Anti-FcRn franchise—endocrine diseases Anti Fc Rn Franchise Endocrine Diseases [Member] Endocrine disease is an autoimmune disease that affects the thyroid gland. Business Combination [Axis] Business Combination [Axis] Comprehensive (loss) income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Noncontrolling Interests Noncontrolling Interest [Member] Marketable securities Marketable Securities [Abstract] Ownership (%) Equity Method Investment, Ownership Percentage Total deferred tax assets/(liabilities) Deferred Tax Assets, Net PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Forfeited/Canceled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Cash, Cash Equivalents and Marketable Securities Cash, Cash Equivalent, and Marketable Security [Text Block] Stock Repurchase Program Stock Repurchase Program [Member] A program to buyback its own share. Certain Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Net (loss) income per common share, diluted: Earnings Per Share, Diluted [Abstract] RSL 2015 EIP Two015 Stock Based Incentive Compensation Plan [Member] The Company's stock-based incentive compensation plan. Number of trading days to meet earn-out price threshold Number of Trading Days to be used to Meet Earn-Out Share Price Threshold The number of trading days that are allowed to meet earn-out share price during vesting period, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Scenario [Axis] Scenario [Axis] Cash and cash equivalents Cash and Cash Equivalent [Abstract] Carrying amount of noncontrolling interest derecognized Disposal Group, Noncontrolling Interest, Derecognized Value The carrying amount of noncontrolling interest derecognized attributable to disposal group held for sale. Proceeds from issuance of the Company’s common shares, net of issuance costs paid Proceeds from Issuance of Common Stock All Individuals All Individuals [Member] At-the-Market Equity Offering Program Equity Offerings at the Market [Member] Offering of "at-the-market" shares as per equity distribution agreement. Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Name Forgone Recovery, Individual Name Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Payment of subsidiary dividend Payments of Subsidiary Dividends Cash outflow in the form of capital distributions and subsidiary dividends to common shareholders, preferred shareholders and noncontrolling interests. Disposal Group Classification [Axis] Disposal Group Classification [Axis] Other Other [Member] It includes the greater china and united kingdom activity. Audit Information [Abstract] Audit Information Private Placement Private Placement [Member] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Liability instruments measured at fair value Liability Instruments Measured at Fair Value Amount of liability instruments measured at fair value. Geographical [Axis] Geographical [Axis] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Anti-FcRn franchise—contractual costs related to batoclimab program discontinuation Anti-FcRn Franchise Contractual Costs Related To Batoclimab Program Discontinuation [Member] Anti-FcRn Franchise Contractual Costs Related To Batoclimab Program Discontinuation Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Schedule of Activity for Stock Options and Performance Stock Options Schedule Of Share Based Compensation Stock Options And Performance Options Activity [Table Text Block] Schedule Of Share Based Compensation Stock Options And Performance Options Activity. Forecast Forecast [Member] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Schedule of Operating Lease Right-of-use Assets and Lease Liabilities Lessee, Operating Lease, Disclosure [Table Text Block] Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions. Title of 12(b) Security Title of 12(b) Security Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Earnings Per Share [Abstract] Earnings Per Share [Abstract] 2031 Lessee, Operating Lease, Liability, to be Paid, Year Five Equity method investment, ownership percentage Subsidiary, Ownership Percentage, Parent Share price (in dollars per share) Share Based Compensation Arrangement by Share Based Payment Award, Share Price at Tranche Performance Period The share price of PSUs allocate in each tranche at specified performance period of trading days. Foreign-derived intangible income Effective Income Tax Rate Reconciliation, FDII, Percent Schedule of Potentially Dilutive Common Stock Equivalents Excluded from Computation of Diluted Net (Loss) Income per Common Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Federal research tax credit carryforwards Tax Credit Carryforward, Amount Stock options and performance stock options Stock Options and Performance Stock Options [Member] Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time and Share-based payment arrangement awarded for meeting performance target. Nondeductible executive compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation, Percent Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation, Percent Percentage of stock purchase price equal to lower of closing price under ESPP Percentage of Stock Purchase Price Equal to Lower of Closing Price Percentage of stock purchase price equal to lower of closing price on first and last trading day of the offering period in which the eligible employees can buy shares under the Employee stock purchase plan. Schedule of Consolidated Financial Information Equity Method Investment, Summarized Financial Information [Table Text Block] Tabular disclosure of financial information for equity method investments. Fourth Tranche Share-Based Compensation Award, Tranche Fourth [Member] Fourth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period. Issuance of the Company’s common shares related to settlement of warrants Stock Issued During Period, Value, Common Share Related to Settlement of Warrants Value Aggregate change in value issuance of the company's common share related to settlement of warrants value. Anti-FcRn franchise—neurological diseases Anti Fc Rn Franchise Neurological Diseases [Member] Neurological disorders represent a complex array of medical conditions that fundamentally disrupt the functioning of the nervous system. These disorders affect the brain, spinal cord, and nerve networks, presenting unique diagnosis, treatment, and patient care challenges. Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Sixth Tranche Share-Based Compensation Award, Tranche Sixth [Member] Sixth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period. Award Timing Disclosures [Line Items] 20% Earn-Out Twenty Percent Earn-Out Shares [Member] The percentage of earnout shares. Lessee, operating lease, renewal term Lessee, Operating Lease, Renewal Term Legal settlements paid Payments for Legal Settlements Earn-Out Shares, Public Warrants and Private Placement Warrants Earn-Out Shares, Public Warrants and Private Placement Warrants [Text Block] The entire disclosure of earn-out shares, public warrants and private placement warrants. Shareholders' Equity Equity [Text Block] Other income, net Disposal Group Including Discontinued Operation Other (Income) Expense, Net Amount of other (income) expense, net attributable to disposal group, including, but not limited to, discontinued operation. Net (loss) income attributable to Roivant Sciences Ltd. Net Income (Loss) Attributable to Parent Equity Method Investment, Nonconsolidated Investee [Domain] Equity Method Investment, Nonconsolidated Investee [Domain] Weighted-average grant date fair value per share of stock options granted (in dollars per share) Sharebased Compensation Arrangement by Sharebased Payment Award, Options, Granted, Weighted Average Grant Date Fair Value Weighted average grant-date fair value of options granted. Other expenses Other Accrued Liabilities, Current Schedule of Reconciliation of Income Tax Expense Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Performance of grant date Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Interest expense Disposal Group, Including Discontinued Operation, Interest Expense Other Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Segment Information [Line Items] Segment Reporting Information [Line Items] Repurchase of the Company’s common shares Payments for Repurchase of Common Stock Adoption Date Trading Arrangement Adoption Date Other general and administrative expenses Other General and Administrative Expenses [Member] Represents Other General and Administrative Expenses. Genevant Sciences Ltd. Genevant Sciences Ltd. [Member] Genevant Sciences Ltd. General and Administrative Expenses Selling, General and Administrative Expenses, Policy [Policy Text Block] (Loss) income from operations Income (loss) from operations Operating Income (Loss) Schedule of Calculation of Gain Schedule of Gain on Sale of Assets Calculation [Table Text Block] Tabular disclosure of information related to the calculation of the gain on sale of assets. Issuance of the Company's common shares related to settlement of warrants (in shares) Stock Issued During Period, Value, Common Share Related to Settlement of Warrants Shares Number of shares issued common share related to settlement of warrants shares. (Accumulated deficit) / retained earnings Retained Earnings (Accumulated Deficit) Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Equity incentive plan term Equity Incentive Plan Term Equity incentive plan term, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Realized gain from sales of marketable securities Realized Gain (Loss), Sales Of Marketable Securities, Operating Realized Gain (Loss), Sales Of Marketable Securities, Operating Net proceeds from sale of common stock Net Proceeds from Issuance of Common Stock The net cash inflow from the additional capital contribution to the entity. Schedule of Activity of PSU's Performance Condition Share-Based Compensation Arrangements by Share-Based Payment Award, Performance-Based Units, Vested and Expected to Vest [Table Text Block] Purchases Payments to Acquire Held-to-Maturity Securities Class of Stock [Axis] Class of Stock [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Operating expenses: Disposal Group Including Discontinued Operating Expenses [Abstract] Disposal Group Including Discontinued Operating Expenses [Abstract] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Underwritten Public Offering Underwritten Public Offering [Member] Public offering in which the Common Stock is offered and sold on a firm commitment basis through one or more underwriters. Other liabilities Deferred Tax Liabilities, Other Statement [Table] Statement [Table] Other (income) expense, net Other (income) expense, net Other Nonoperating Income (Expense) States in U.S and Canada United States And Canada [Member] United States and Canada. Total deferred tax benefit Deferred Income Tax Expense (Benefit) Effect of exchange rate changes on cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Adjustments to reconcile net (loss) income to net cash used in operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Cash flows from financing activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Risk-free rate Measurement Input, Risk Free Interest Rate [Member] Permanent disallowed IPR&D Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent Schedule of Changes in Fair Value of the Level 3 Assets Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] All Adjustments to Compensation All Adjustments to Compensation [Member] Amendment Flag Amendment Flag Sale of stock, price (in dollars per share) Sale of Stock, Price Per Share Share-based compensation arrangement by share-based payment award, number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Software Software Development [Member] Termination Date Trading Arrangement Termination Date Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Third Tranche Share-Based Payment Arrangement, Tranche Three [Member] Issuance of subsidiary shares in connection with debt renegotiation Issuance of subsidiary Shares in Connection with Debt Renegotiation Amount of subsidiary shares issued in consideration for debt renegotiation. Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Interest and penalties related to unrecognized tax benefits Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Schedule of Computation of the Numerator to Derive the Basic and Diluted Net (Loss) Income Per Common Share Amounts Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Director Director [Member] Options exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Related Party Transaction [Domain] Related Party Transaction [Domain] Segment Reporting [Abstract] Segment Reporting [Abstract] Scenario [Domain] Scenario [Domain] Earn-Out Shares, Public Warrants and Private Placement Warrants [Line Items] Earn-Out Shares, Public Warrants and Private Placement Warrants [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Mosliciguat Mosliciguat [Member] Mosliciguat it is an inhaled soluble guanylate cyclase activator developed by Bayer for pulmonary arterial hypertension. Number of patents Litigation Settlement, Number Of Patents Litigation Settlement, Number Of Patents Income Taxes [Table] Income Taxes [Table] Disclosure of information about income taxes. Acquired in-process research and development Acquired in Process Research and Development Expense Amount of acquired in-process research and development expense. Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Consolidated Entities [Axis] Consolidated Entities [Axis] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Dermavant Dermavant [Member] Name of the acquiree. Granted (in shares) Granted, stock options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Assets sold Disposal Group, Assets Amount classified as assets attributable to disposal group held for sale. Telavant Holdings, Inc Telavant Holdings, Inc [Member] Name of the entity. President and Immunovant CEO President and Immunovant CEO [Member] President and Immunovant CEO Use of Estimates Use of Estimates, Policy [Policy Text Block] Address Type [Domain] Address Type [Domain] Insider Trading Arrangements [Line Items] 10 % Earn-Out Ten Percent Earn-Out Shares [Member] The percentage of earn-out shares. Wholly-owned Subsidiaries Address - NY Wholly-owned Subsidiaries Address - NY [Member] Wholly-owned Subsidiaries Address - NY Total liabilities Liabilities Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] One-Time Cash Retention Awards One-Time Cash Retention Awards [Member] A retention bonus is a targeted one-time payment that is offered as an incentive to keep a key employee on the job. RSL Equity Plans Roivant Sciences Ltd Equity Plans [Member] The Roivant Sciences Ltd. 2021 Equity Incentive Plan (the "RSL 2021 EIP"), the Roivant Sciences Ltd. Amended and Restated 2015 Equity Incentive Plan, and the Roivant Sciences Ltd. Amended and Restated 2015 Restricted Stock Unit Plan (collectively, the "RSL Equity Plans"). Acquired In-Process Research and Development Expenses In Process Research and Development, Policy [Policy Text Block] Proceeds from sale of Telavant net assets, net Proceeds from Sale of Assets The cash inflow from the sale of assets. Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Marketable securities, held-to-maturity Marketable Securities, Held-to-Maturity [Abstract] Marketable Securities, Held-to-Maturity Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Bayer AG (Pulmovant, Inc.) Bayer AG (Pulmovant, Inc.) [Member] Name of the entity. Schedule of Long-Term Equity Incentive Awards Approved Schedule Of Share Based Compensation Equity Incentive Awards Approved [Table Text Block] Tabular disclosure of share based compensation equity incentive awards approved activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value. Counterparty Name [Axis] Counterparty Name [Axis] Schedule of Activity for RSUs Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Proceeds from maturities Proceeds from Maturities, Prepayments and Calls of Held-to-Maturity Securities Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Non-NEOs Non-NEOs [Member] Percentage of annual net sales Percentage of Net Sales for Future Royalty Payments The percentage of net sales for future royalty payments Corporate bonds Corporate Debt Securities [Member]